1. Home
  2. INTA vs TYRA Comparison

INTA vs TYRA Comparison

Compare INTA & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intapp Inc.

INTA

Intapp Inc.

HOLD

Current Price

$24.96

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$33.91

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTA
TYRA
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
INTA
TYRA
Price
$24.96
$33.91
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$41.43
$47.50
AVG Volume (30 Days)
709.9K
964.0K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
48.89
N/A
EPS
N/A
N/A
Revenue
$504,120,000.00
N/A
Revenue This Year
$15.91
N/A
Revenue Next Year
$13.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.09
N/A
52 Week Low
$19.24
$8.75
52 Week High
$58.79
$40.65

Technical Indicators

Market Signals
Indicator
INTA
TYRA
Relative Strength Index (RSI) 57.92 44.77
Support Level $24.60 $33.81
Resistance Level $26.51 $33.99
Average True Range (ATR) 1.19 2.18
MACD 0.33 -0.28
Stochastic Oscillator 97.68 26.37

Price Performance

Historical Comparison
INTA
TYRA

About INTA Intapp Inc.

Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: